Table 6.

Rates of other renal manifestations at baseline in overall population and by mutational status.

	Overall N = 2,211	Patients with TSC1 mutationN = 196	Patients with TSC2 mutation N = 654
Renal manifestations in patients with angiomyolipomas
Multiple renal cysts	544 (24.6)	26 (13.3)	220 (33.6)
Polycystic kidneys	Not applicable*	0	31 (4.7)
Renal malignancy	31 (1.4)	4 (2.0)	8 (1.2)
Renal manifestations in patients without angiomyolipoma
Impaired renal function	43 (1.9)	6 (3.1)	18 (2.8)

CI, confidence interval; mTOR, mammalian target of rapamycin; N/A, not applicable; TSC, tuberous sclerosis complex.

Values are expressed as n (%).

^*PKD was observed only in those with TSC2 mutations.